oncoReveal® CDx Pan-Cancer Solid Tumor IVD
oncoReveal™ CDx is an FDA PMA-approved, NGS-based companion diagnostic (CDx) kit providing comprehensive genomic results, covering 22 clinically relevant genes. oncoReveal CDx has a single-tube workflow that can be performed by any clinical laboratory, providing sample-to-clinical report in less than 48 hours.
Long Description
oncoReveal® CDx Pan-Cancer Solid Tumor IVD has been clinically and analytically validated across all major solid tumors. The assay kit is designed to provide clinically actionable information — both to consider appropriate CDx therapies in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), and to aid in the identification of other clinically significant genomic alterations for patients with solid tumors.
High Resolution Image
Small Image
Large Image
Category Product Showcase